Rating #89
Nathaniel August
Mangrove Partners
Portfolio value
Stocks
Performance
1 Year
+23.67%
Stock Holdings
$
%
1Y
3Y
5Y
10Y
Nathaniel August’s Portfolio: Q4 2025
Top10 stocks: 47.45% of the portfolio
Nathaniel August’s Trades: Q4 2025
Adds
New Buys
Sold Outs
Cuts
1.48ppt
0.61ppt
0.13ppt
0.11ppt
0.08ppt
0.54ppt
0.08ppt
0.09ppt
0.08ppt
0.09ppt
Company Name | Share Count Chg. (%) | Price Paid | Buy Value | Portfolio % Change | |
|---|---|---|---|---|---|
1  REX | Add +92.81% | $32.57 | $15.92M | 1.48ppt | |
2  BILL | Add +11.45% | $51.37 | $3.46M | 0.61ppt | |
3  SOCA | Add +300.00% | $10.08 | $1.51M | 0.13ppt | |
4  CVNA | Add +100.00% | $371.73 | $1.18M | 0.11ppt | |
5  AXON | Add +100.00% | $620.52 | $1.13M | 0.08ppt | |
6  FLYW | Add +2.84% | $13.69 | $1.13M | 0.54ppt | |
7  BABA | Add +100.00% | $162.86 | $1.07M | 0.08ppt | |
Add +80.00% | $10.03 | $1.00M | 0.09ppt | ||
9  JCI | Add +100.00% | $114.81 | $979.90K | 0.08ppt | |
10  GH | Add +100.00% | $89.46 | $960.53K | 0.09ppt |
Nathaniel August’s Holdings: Q4 2025
Company Name | Primary Industry | Avg. price paid  | Share Count Chg. (%) | No of shares held | Market value | Portfolio % Change | % of Ownership | Holding period | Last Transaction | |
|---|---|---|---|---|---|---|---|---|---|---|
1  INDV | Pharmaceutical Pres | $15.02 | Add +0.13% | 2.75M | $98.53M | 8.03% 3.14ppt | 2.20% | 6 Quarters | Q4 2025 | |
2  RIO | Metal Mining | $61.66 | 0.00% | 998.66K | $79.92M | 6.51% 1.64ppt | 0.06% | 7 Quarters | Q1 2025 | |
3  ATMU | Vehicle Parts | $26.92 | Cut -1.15% | 1.32M | $68.27M | 5.56% 1.13ppt | 1.60% | 10 Quarters | Q4 2025 | |
4  TEVA | Pharmaceutical Pres | $15.00 | Cut -7.67% | 2.16M | $67.38M | 5.49% 2.00ppt | 0.19% | 8 Quarters | Q4 2025 | |
5  ECVT | Chemicals & Products | $6.64 | Cut -0.48% | 5.45M | $53.01M | 4.32% 0.78ppt | 4.78% | 4 Quarters | Q4 2025 | |
6  BDX | Surgical Instruments | $152.56 | New Buy +100.00% | 247.32K | $48.00M | 3.91% 3.91ppt | 0.11% | 1 Quarter | Q4 2025 | |
7  ENVA | Personal Credit Institutions | $44.67 | Cut -42.34% | 286.54K | $45.04M | 3.67% -0.56ppt | 1.16% | 15 Quarters | Q4 2025 | |
8 FLYW | Other Business Services | $13.56 | Add +2.84% | 2.98M | $42.25M | 3.44% 0.54ppt | 2.44% | 2 Quarters | Q4 2025 | |
9  MRP | Real Estate | $27.74 | Cut -4.22% | 1.38M | $41.25M | 3.36% -0.22ppt | 0.83% | 4 Quarters | Q4 2025 | |
10  PCG | Combined Electric Services | $15.08 | Cut -7.06% | 2.41M | $38.79M | 3.16% 0.27ppt | 0.11% | 2 Quarters | Q4 2025 | |
11  BIO | Lab Analytical Instruments | $280.39 | 0.00% | 126.85K | $38.44M | 3.13% 0.50ppt | 0.47% | 2 Quarters | Q3 2025 | |
12 BILL | Prepackaged Software | $53.13 | Add +11.45% | 655.37K | $35.74M | 2.91% 0.61ppt | 0.65% | 2 Quarters | Q4 2025 | |
13  ELME | Real Estate Investment Trusts | $16.86 | 0.00% | 2.05M | $35.59M | 2.90% 0.35ppt | 2.32% | 2 Quarters | Q3 2025 | |
14  FIS | Other Business Services | $66.46 | New Buy +100.00% | 507.39K | $33.72M | 2.75% 2.75ppt | 0.10% | 1 Quarter | Q4 2025 | |
15 REX | Organic Chemicals | $31.44 | Add +92.81% | 1.02M | $32.81M | 2.67% 1.48ppt | 3.05% | 2 Quarters | Q4 2025 | |
16  OTEX | Integrated Systems Design | $29.20 | Cut -5.60% | 993.20K | $32.35M | 2.64% -0.27ppt | 0.39% | 3 Quarters | Q4 2025 | |
17  TFX | Surgical Instruments | $122.04 | New Buy +100.00% | 256.73K | $31.33M | 2.55% 2.55ppt | 0.58% | 1 Quarter | Q4 2025 | |
18  NWSA | Newspaper publishing | $29.16 | 0.00% | 1.19M | $31.13M | 2.54% -0.17ppt | 0.21% | 4 Quarters | Q3 2025 | |
19  TPB | Tobacco | $72.72 | Add +1.61% | 265.21K | $28.75M | 2.34% 0.44ppt | 1.45% | 17 Quarters | Q4 2025 | |
20  CODI | Household Furniture | $6.39 | 0.00% | 3.68M | $17.69M | 1.44% -0.36ppt | 4.90% | 3 Quarters | Q3 2025 |
NEWSLETTER
NEWSLETTER
Market data is sourced from S&P Global Market Intelligence. All insights and analysis are developed by Gainify. Copyright © 2026, S&P Global Market Intelligence. All rights reserved.
View Data ProvidersOur content is general in nature and does not account for your personal financial circumstances. Any investment decisions you make are your responsibility. We strongly recommend speaking with a licensed financial advisor or professional before acting on any information found on Gainify. Before using Gainify, please review our Terms of Service.